ProfileGDS5678 / 1440279_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 92% 91% 90% 92% 91% 87% 90% 90% 90% 91% 92% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.5832292
GSM967853U87-EV human glioblastoma xenograft - Control 27.7054292
GSM967854U87-EV human glioblastoma xenograft - Control 37.5161891
GSM967855U87-EV human glioblastoma xenograft - Control 47.4125890
GSM967856U87-EV human glioblastoma xenograft - Control 57.7380692
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.2480391
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4918387
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.248390
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1154890
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2732290
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4128291
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.6298692
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3707391
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.3830391